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Purpose
To determine the prognostic and predictive value of
tumor infiltrating lymphocytes (TIL) in colon cancer in
a cohort of patients who previously took part in a trial
on adjuvant Active Specific Immunotherapy (ASI).
Background information
Vermorken et al.[1] conducted a multicenter clinical trial
on adjuvant ASI for colon cancer patients. A vaccine
consisting of irradiated autologous tumor cells admixed
with the adjuvant Bacillus Calmette-Guérin bacteria has
been evaluated. In that study, a comparison was made
between surgery alone and surgery followed by adjuvant
ASI treatment. The recurrence free interval for patients
with stage II tumors was significantly extended for
patients treated with surgery plus ASI compared to sur-
gery alone, but not for stage III patients. A follow up
study by de Weger et al.[2] showed that patients with
stage II microsatellite stable tumors (MSS) benefited
most from ASI treatment. The data on patients with
microsatellite instable tumors (MSI) were inconclusive.
Current experimental design
Here we determined the number and location of CD3+
and CD8+ cells in archival tumor samples of 106 MSS
colon cancers. Disease specific survival (DSS) and recur-
rence free interval (RFI) were evaluated in detail at the
5 year post-treatment time point. First, we investigated
the prognostic value of stromal and intraepithelial T cell
infiltrates independent of treatment arm. Second, we
investigated the predictive value of stromal and intrae-
pithelial T cell infiltrates for clinical outcome after ASI
treatment. For the analysis we used continuous data on
T cell counts comparing the treatment effect of adjuvant
Active Specific Immunotherapy in patients with high
TIL to the treatment effect in low TIL.
Results
Based on the data presented we concluded that 1) high
numbers of stromal CD3 T cells have positive prognostic
value measured as DSS for patients with stage II MSS
tumors, and 2) high numbers of epithelial CD8 positive
T cells have positive prognostic value measured as RFI for
the group of patients with stage II MSS tumors as well as
for the whole group (stage II plus stage III together).
Furthermore we concluded that high numbers of preexist-
ing stromal CD3 positive T cells are of positive predictive
value in adjuvant ASI treatment measured as DSS as well
as RFI.
Conclusion
ASI therapy contributes to an improved DSS and RFI in
patients with MSS colon tumors harboring high numbers
of preexisting stromal CD3+ TIL.
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